Catholic University Catholic Hematology Hospital

Advanced Materials published our preclinical results on personalized cancer vaccine therapy in acute myeloid leukemia patients.

HemaSphere published our single-cell analysis results for patients with aplastic anemia undergoing immunosuppressive therapy.

The importance of comprehensive geriatric assessment in elderly patients with acute myeloid leukemia and the treatment efficacy of decitabine+venetoclax were published in Blood and Blood Cancer Journal, respectively.

Experimental and Molecular Medicine featured our evaluation of Bortezomib treatment response in multiple myeloma patients through single-cell analysis.

Results from two phase III studies on allogeneic transplantation at Catholic Blood Hospital were published in the American Journal Of Hematology, covering a comparison of haploidentical family member transplantation vs. unrelated donor transplantation and the preventive effect of low-dose thymoglobulin in sibling transplantation for chronic graft-vs-host disease.

During the COVID-19 pandemic, we maintained normal medical services for severe blood disorders, a first for Korea, published in the British Journal of Haematology.

Blood also published our first global research on the effectiveness of the new C5 complement inhibitor Ravulizumab, showing it to be as effective as eculizumab in treating paroxysmal nocturnal hemoglobinuria.

The Lancet Haematology highlighted our work on the effectiveness of Romiplostim in treating resistant aplastic anemia.

The New England Journal of Medicine published our world-first findings on the treatment outcomes using fourth-generation tyrosine kinase inhibitors for chronic myelogenous leukemia that is resistant or intolerant.

The prestigious Annals of Oncology published our world-first research on improving treatment outcomes in adult Philadelphia chromosome-positive acute lymphoblastic leukemia through combining imatinib with chemotherapy.

Our research on the anti-leukemic effects of the new CXCR4 inhibitor LY2510924 was published in Blood.

We achieved successful immune tolerance in kidney transplantation through hematopoietic stem cell transplantation.

Our team successfully completed an allogeneic hematopoietic stem cell transplantation for a thalassemia major patient in Abu Dhabi.

We conducted Korea's first T/NK cell therapy.

Our groundbreaking work on improving outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, using pre-transplant imatinib treatment, was the first to be published in Blood, a leading hematology journal.

Globally, we were the first to successfully perform a liver transplantation after an allogeneic hematopoietic stem cell transplantation.

We were pioneers in conducting the first successful haploidentical family member transplantation in Korea.

We broke new ground with the first successful transplantation for autoimmune diseases in Korea, specifically for Multiple Sclerosis.

Our team achieved the first successful non-myeloablative allogeneic hematopoietic stem cell transplantation in Korea.

We were the first in Korea to successfully perform an umbilical cord blood transplantation.

Another first in Korea was our successful transplantation from a non-related, matched donor.

We also led the first successful autologous hematopoietic stem cell transplantation in Korea.

In March, we achieved a groundbreaking success in Korea by performing the first successful allogeneic hematopoietic stem cell transplantation on an adult with lymphoblastic leukemia.

Also in March, we restructured to introduce an Hematology Hospitalist Center, which includes 7 specialized centers.

In March, Seoul St. Mary's Hospital opened a specialized Hematology Hospital.

We began cooperation with a hematopoietic stem cell bank in the United States, extending our reach globally.

We kicked off collaboration with a hematopoietic stem cell bank in Germany, strengthening our international connections.

We initiated a partnership with a hematopoietic stem cell bank in Taiwan, representing our efforts in the Asian region.

We started collaborating with a hematopoietic stem cell bank in Japan, further expanding our network in Asia.

In December, we expanded and upgraded to become the largest hematopoietic stem cell transplantation center in Asia.

We established Korea's first Catholic Hematopoietic Stem Cell Bank.

In May, we launched Korea's first Catholic Bone Marrow Transplant Center.

We became the first in Korea to register with the International Bone Marrow Transplant Registry.

Another business agreement was signed in August, this time with GENOMEinSIGHT Inc.

In February, LOKKS307 Inc. became a new business partner.

In March, we also partnered with iKooB Inc.

In August, a business agreement was forged with Eutilex

In December, we teamed up with Imprimed Korea Inc.

In March, we entered into a business partnership with the Seocho Symphony Orchestra.

In May, we signed a business agreement with VUNO Inc.

In September, we established a partnership with the Center for Genomic Integrity (CGI), Institute of Basic Science (IBS)